Drugs / CAR.B7-H3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04670068 | Jan 2021 → Dec 2024 overdue | malignant epithelial tumor of ovary | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR.B7-H3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04670068 ↗ |
| Modality | Cell therapy | “autologous T lymphocyte chimeric antigen receptor cells” NCT04670068 ↗ |
| Route | Other | “The CAR.B7-H3 T cells are given through a catheter in the abdomen” NCT04670068 ↗ |